Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease.

ABSTRACT:

Background

High-dose influenza vaccine (HDV) is an alternative vaccination strategy in patients with end-stage renal disease (ESRD), though the safety of HDV has not been evaluated in this population. The objective of this study was to estimate the relative occurrence of adverse vaccine reactions in patients with ESRD following vaccination with HDV compared with standard-dose influenza vaccine (SDV).

Methods

Using data from the United States Renal Data System, we identified patients with ESRD aged ≥ 65 years at influenza vaccination during yearly influenza seasons from 2010 through 2016. Patients were followed after vaccination to observe serious (anaphylaxis, angioedema, seizure, encephalopathy, Guillain-Barré syndrome [GBS], and short-term, all-cause mortality) and milder

SUBMITTER: Layton JB 

PROVIDER: S-EPMC7332402 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature